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RESOLUSI KINETIK TERHADAP RASEMIK ACEBUTOLOL
MENGGUNAKAN PERANTARAAN LIPASE CANDIDA ANTARTICA B
ABSTRAK
Asebutolol masih lagi dipasarkan dalam bentuk rasemik sehingga kini.
Kecenderungan terhadap penghasilan enantiomer tunggal bagi ubat-ubatan berbentuk
kiral adalah didorong oleh beberapa faktor antaranya kesan yang berbeza daripada
enantiomer tersebut, permintaan dalam pasaran yang semakin meningkat, juga
peraturan yang semakin ketat terhadap pengeluaran ubat-ubatan tersebut. Oleh itu,
resolusi kinetik terhadap rasemik asebutolol dikaji menggunakan perantaraan lipase
dalam reaktor kelompok dan reaktor membran berenzim. Kaedah sambutan
permukaan dengan rekabentuk central composite design (CCD) digunakan untuk
analisis data bagi reaktor kelompok. Faktor yang dikaji adalah merangkumi jumlah
enzim, kepekatan substrat dan penderma asil dan suhu tindakbalas. Kajian mendapati
bahawa tindabalas di dalam reaktor kelompok ini mencapai optimum dengan 320 mg
enzim, 50 mM kepekatan Asebutolol, 140 mM kepekatan vinil asetat and suhu 40 oC,
memberikan kadar pertukaran sebanyak 46% dengan nilai E dan ees masing-masing
15 and 73%. Tenaga pengaktifan dan penyahtabii bagi enzim di dalam reaktor
kelompok dalam kajian ini dianggarkan masing-masing sebanyak 39.63 kJ/mol dan
54.90 kJ/mol. Pemalar pendeaktifan kd meningkat sebanyak 0.012-0.031 per jam
dengan peningkatan suhu daripada 45 oC ke 60 oC. Nilai entalpi adalah 52.12
kJ/mol.K dan entropi adalah -0.18 kJ/mol.K. Berdasarkan dapatan daripada tindak
balas di dalam reaktor kelompok, resolusi kinetik Acebutolol telah berjaya dilakukan
di dalam reaktor membran berenzim. Kesan jumlah enzim, kepekatan substrat dan
xviii
penderma asil, pH larutan penimbal, suhu tindakbalas, kadar aliran fasa organik dan
tekanan transmembran. Tindakbalas di dalam reaktor membran berenzim mencapai
nilai optimum pada pH 7, 40 oC dan TMP 6 psi, dengan kadar aliran fasa organik
sebanyak 40 ml/min. Ia memberikan nilai pertukaran 40%, E sebanyak 23 dan ees
sebanyak 84%. Tindakbalas enzim di dalam reaktor kelompok dan reaktor membran
berenzim kedua-duanya mematuhi mekanisme Ping Pong Bi Bi. Parameter kinetik
untuk enzim bebas di dalam reaktor kelompok adalah seperti berikut: KMace =8.53
mM, KMva =5.19 mM, dan Vmax =1.18 mM/h. Manakala parameter kinetik untuk
enzim tersekatgerak di dalam reaktor membran berenzim adalah seperti berikut;
Kmace app = 2.13 mM, KMvaapp = 1.23 mM dan Vmax app =2.33 mM/h. Nilai pemalar
perencat pula adalah KIace=10.72 mM, KIva,= 3.71 mM, KIace app = 11.56 mM dan KIva
app=3.89 mM. Prestasi CALB di dalam kedua-dua jenis reaktor telah dibandingkan.
Enzim tersekatgerak di dalam reaktor membran berenzim memberikan kapasiti
tindak balas yang lebih tinggi, kestabilan terma yang lebih baik, afiniti yang lebih
tinggi kepada substrat dan juga menunjukkan rintangan tinggi terhadap kesan
perencat berbanding enzim bebas di dalam reaktor kelompok. Kelebihan enzim
tersekatgerak dilihat amat berpotensi untuk diaplikasikan dalam industri penghasilan
enantiomer tunggal, terutamanya penyekat beta dalam masa terdekat.
xix
CANDIDA ANTARTICA LIPASE B  MEDIATED KINETIC RESOLUTION
OF RACEMIC ACEBUTOLOL
ABSTRACT
Acebutotol is still available in racemic form. The increasing preference for single or
pure enantiomer of chiral drugs is  driven mainly by the different effects of the
enantiomers, the high market demand and the guidelines issued by regulatory
authorities. Therefore, the kinetic resolution of racemic acebutolol is studied in batch
and enzymatic membrane reactor. The response surface methodology based on
central composite design (CCD) was employed for optimization and analysis of
kinetic resolution of racemic acebutolol  in a batch reactor. The process variables
which were taken into account include; enzyme loading, substrate concentration, acyl
donor concentration and temperature. The optimum conditions were found to be  320
mg of enzyme loading, with  acebutolol concentration of 50 mM, vinyl acetate
concentration of  140 mM and temperature at 40 oC, giving the overall conversion of
46.6%. The value of enantioselectivity E and enantiomeric excess of the substrate ees
were found to be 15 and 73%, respectively. Lipase activation and deactivation
energy was estimated to be 39.63 kJ/mol and 54.90 kJ/mol, respectively.
Denaturation constant, kd was increasing from 0.012-0.031 h-1 with the increasing
temperature from 45 0C to 60 0C. The value of enthalpy and entropy for free Candida
antartica lipase B were 52.12 kJ/mol.K and -0.18 kJ/mol.K, respectively. Based on
the finding from the batch reaction, kinetic resolution of acebutolol has been
successfully conducted in enzymatic membrane reactor (EMR). The effects of
enzyme loading, substrate and acyl donor concentration, pH of buffer solution,
xx
reaction temperature, and organic phase flow rates,  and transmembrane pressure
(TMP) were investigated. The optimum operating conditions for the lipase-catalyzed
kinetic resolution in an EMR system were pH 7, 40 oC and TMP of 6 psi at organic
flow rate of 40 ml/min. This condition gave 40% overall conversion,
enentioselectivity of 23 and ees of 84%. The reaction kinetic was found to obey the
Ping Pong Bi Bi mechanisms for both free and immobilized lipase from Candida
antartica B . The kinetic parameters for the free lipase were: KMace =8.53 mM, KMva
=5.19 mM, and Vmax =1.18 mM/h. The apparent kinetic parameters for the
immobilized lipase were: Kmace app = 2.13 mM, KMvaapp = 1.23 mM and Vmax app =2.33
mM/h. The kinetics of kinetic resolution accounted for both substrates inhibitions.
The inhibition constants were given by KIace=10.72 mM, KIva,= 3.71 mM, KIace app =
11.56 mM and KIva app=3.89 mM. The performance of free and immobilized CALB
were compared. The immobilized lipase in EMR gave higher reaction capacity,
better thermal stability, higher affinity to the substrates and exhibited higher
resistance towards the inhibition effect. The advantages of  immobilized enzyme
makes it possible for economical industrial production of chiral drugs, particularly
beta blockers  in the near future.
1CHAPTER 1
INTRODUCTION
1.1 Chiral Drugs in Pharmaceutical Industries
The word chiral is derived from the greek word cheir, meaning hand, to
describe the handedness of the molecule. An object is said to be chiral if its two
mirror image forms are not superimposable in the three dimension. The opposite of
chiral is achiral (Morris, 2002).
A pair of stereoisomers that are non-superimposable mirror images of one
another is called enantiomer. They have different three dimension configurations.
Whereas, the mixture of two enantiomers in equal portion is referred to as a
racemate. Enantiomers can be named by different methods. For example, prefixes
(R) and (S) can be used for right hand and left hand enantiomers, respectively. The
other methods are by using (+) and (-) or D and L (Sheldon, 1993). This general
prefix applies to all bioactive substances including pharmaceutical compounds
(Sheldon, 1996).
In an achiral environment, the enantiomers of chiral drugs show similar
physical and chemical properties. Both enantiomers have identical  molecular
weight, solubility and melting point. However, in a chiral environment, the chemical
and pharmacologic behaviors of the enantiomers may be differ (Somogyi, 2004;
Caldwell, 2001). Drugs work by binding to the specific biological sites (or drug
binding sites), such as proteins (receptors, enzymes), nucleic acids (DNA and RNA)
and biomembranes (phospholipids and glycolipids) present in the body.
2Our body, which consists of numerous homochiral compound interacts with
racemic drugs differently and metabolize each enantiomer by separate pathways, thus
generate different pharmacological activity. One enantiomer may produce the desired
healing effects, while the other may be inactive or produce undesired effects. In
pharmacology, the active enantiomer is known as eutomer, while the inactive
enantiomer is referred as distomer (Nguyen et al., 2006 and Shafaati, 2007).
Figure 1.1 illustrates the molecular mechanism of chiral pharmacology and
toxicity, which is highly affected by the interaction between a chiral drug and its
chiral binding site. As shown in the figure, the portion of the drug labeled as A, B
and C. Meanwhile, a, b and c represent the region of the binding site. In order to have
its desired therapeutic effect, A, B, and C must interact with the corresponding a, b,
and c. The three dimensional structure of the eutomer can be aligned with the binding
site in order to allow A to interact with a, B to interact with b, and C to interact with
c. On the other hand, for the distomer, no matter how it is rotated in space, it failed to
bind to its corresponding binding sites simultaneously. As a result, it fails to exert a
desirable effect. In a few cases, the distomer interacts with an unusual binding site
leading to undesirable biological effects (McConathy and Owens, 2003).
3Figure 1.1 : The hypothetical interaction between the two enantiomers of a chiral
drugs and its binding site (McConathy and Owens, 2003; and Vadya, 2011)
1.2 Market Trends of Chiral Drugs
Recently, much attention on the development of chiral  drugs has been
growing rapidly due to the increased awareness in stereochemistry of drugs.  Strict
regulation has been defined by the Food and Drug Administration (FDA).  In order to
patent a new racemic drug, full profiles for both enantiomers as well as the racemic
mixture of the chiral drug has to be documented separately. The information in the
document should provide pharmacological and pharmacokinetic properties of the
new patented drug  (Maier et al., 2001, Viegas et al ., 2007a, Cho et al., 2002).
From the economic point of view, chiral drugs continue to make a significant
contribution to the global pharmaceutical markets. Earlier in 1997, about 50% of the
top 500 drugs are marketed as single enantiomer (Stinson 1998; and Maier et al.,
